Bio-Native SaaS Platform
LensAI
One platform.
Multi-function access.
In-house intelligence. Out-sized advantage. With LensAI™ flexible SaaS, researchers gain direct access to a suite of multi-functional applications and tools—all in one platform. From hit selection to lead refinement, bringing scale, speed, and integration into everyday workflows.
Screening
Applications
LensAI
Scalable SaaS platform for biologics exploration, discovery and design
Validated accuracy matching gold-standard X-ray crystallography.
Identify antibody binding sites with 3D precision.
Demonstrated effectiveness for ADA risk stratification.
Identify high-risk therapeutics.
Automated developability profiling from sequence data.
Evaluate stability, solubility, chemical liabilities, and non-specific binding risks early.
Fully automated, scalable, and ready to run.
From preprocessing to post-analysis—with access to contact, affinity, trajectory data.
Hit selection with 360° biological insight.
Go beyond sequence to reveal structural, physicochemical, and functional relationships—clustering diverse antibodies with shared properties at high-throughput.
Expand hits with functional precision.
Discover diverse, high-value sequences by comparing across sequence, structure, and physicochemical properties—all within one intelligent workflow.
Key benefits:
- Multi-functional tools: run diverse applications in one platform. Hit Expansion, Immunogenicity and more…
- Continuously enriched: every new dataset strengthens the system, informing your project with evolving intelligence
- Scalable access: expand from small projects to large studies instantly, no extra infrastructure
Send us your data—sequence, structure, or complete program context—and see LensAI in action. No integration, no delay—just rapid, high-impact insights delivered. Start with a paid pilot, measure the results, then scale seamlessly to SaaS. A bio-native discovery ecosystem designed to accelerate understanding, refine candidates, and advance discovery toward the clinic.
Subscription based
Discover the full power of LensAI with a subscription model built for flexibility—giving you on-demand access to AI-native biologic intelligence for applications like epitope mapping, deep functional analytics, and scalable insights across every stage of discovery.
New FDA guidance: AI derived data now accepted in IND filings
In January 2025, the FDA clarified that AI-based findings can be part of IND submissions when they’re transparent, reproducible, and traceable. HYFTs® structure and connect complex data to meet those standards—turning AI insight into evidence ready for regulatory review.
One platform. Your workflow. Total flexibility.
See it in action
Request demo